Mathiéu Molimard

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

David Marín, Alexandra Bazeos, François-Xavier Mahon et al. · Journal of Clinical Oncology · 2010 · 901 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Stéphane Picard, Karine Titier, Gabriel Étienne et al. · Blood · 2006 · 604 citations · Full text

Life Sciences, Hematology, Oncology +13

Assessment of Handling of Inhaler Devices in Real Life: An Observational Study in 3811 Patients in Primary Care

Mathiéu Molimard, Chantal Rahérison, S. Lignot et al. · Journal of Aerosol Medicine · 2003 · 398 citations

Pharmacy, Clinical Sciences, Family Medicine +16

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley et al. · Blood · 2011 · 316 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension

Christophe Guignabert, Carole Phan, Andrei Seferian et al. · Journal of Clinical Investigation · 2016 · 273 citations · Full text

Medicine, Oncology, Pharmacology +15